Clinical trial
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients…
NCT00424541 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00424541 |
|---|---|
| Title | Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension |
| Official title | A Multiple Center, Randomized, Double Blind, Parallel Group, Multiple Oral Doses Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profiles of 150 mg and 300 mg of SPP100 in Japanese Patients With Mild to Moderate Essential Hypertension |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | SPP100 (aliskiren) |
| Enrollment | 34 |
| Start date | Jan 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jan 19, 2007 |
| Last update posted | Dec 21, 2020 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: